RecruitingNCT06823960

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

59 participants

Start Date

Dec 9, 2024

Study Type

OBSERVATIONAL

Conditions

Marginal Zone Lymphoma (MZL)

Summary

Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Histologically confirmed diagnosis of relapsed/refractory marginal zone lymphoma
Patients who received at least one dose of zanubrutinib under the Named patient program (D.M. 7 Sep 2017), between January 2021 and October 2023 3) Age≥18 at start of zanubrutinib therapy. 4) Signature of written informed consent to study participation and personal data processing.

Exclusion Criteria1

\) relapsed/refractory marginal zone lymphoma patients who received zanubrutinib in a clinical trial context.

Locations(15)

AOU SS Antonio e Biagio e Cesare Arrigo

Alessandria, Alessandria, Italy

IRCCS-AOU di Bologna

Bologna, Bologna, Italy

P.O. Garibaldi-Nesima_UOC Ematologia

Catania, Catania, Italy

AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia

Cosenza, Cosenza, Italy

AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche

Ferrara, Ferrara, Italy

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

Meldola, Forlì Cesena, Italy

Istituto Clinico Humanitas IRCCS - UO Ematologia

Milan, Milano, Italy

ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia

Milan, MIlano, Italy

IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1

Padua, Padova, Italy

Ospedali Riuniti Villa Sofia - Cervello _ UO di Ematologia ad Indirizzo Oncologico

Palermo, Palermo, Italy

Ospedale Santa Maria delle Croci- OU Ematologia di Ravenna

Ravenna, Ravenna, Italy

Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative

Roma, Roma, Italy

AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia

Torino, Torino, Italy

Ospedale Ca' Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina

Treviso, Treviso, Italy

Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia

Trieste, Trieste, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06823960

Related Trials

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT0513102262 locations

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

NCT074483241 location

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT071219465 locations

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

NCT060430111 location

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

NCT073723651 location